Cerus (CERS) Receivables - Other (2018 - 2021)

Cerus (CERS) posted Receivables - Other of $2.7 million for Q3 2021, down 53.09% sequentially from $5.7 million in Q2 2021.

Cerus (CERS) Receivables - Other (2018 - 2021) Analysis & Trends

Cerus has reported Receivables - Other for 3 years, with the latest figure at $2.7 million in Q3 2021.

Quarterly Receivables - Other changed N/A year-over-year to $2.7 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $2.7 million (changed N/A YoY) and the FY2020 annual result came in at $2.4 million, changed N/A from the prior year.
Receivables - Other slipped to $2.7 million in Q3 2021 per CERS's latest filing, from $5.7 million in the prior quarter.
Over five years, Receivables - Other peaked at $5.7 million in Q2 2021 and troughed at $1.2 million in Q4 2018.
A 3-year average of $3.0 million and a median of $2.7 million in 2021 frame the typical range for Receivables - Other.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn
10	Cerus	560.58 Mn	504.32 Mn	29.53 Mn

Download Data